Showing Results for
- Academic Journals (68)
Search Results
- 68
Academic Journals
- 68
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedA $316.5-million investment fund launched by the London-based Wellcome Trust in March was followed nine days later by news of a $80-million Pioneer Fund, a tie-up between CRT (Cancer Research Technology), the...
- 2From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedThree benchtop high-throughput sequencing instruments are now available. The 454 GS Junior (Roche), MiSeq (Illumina) and Ion Torrent PGM (Life Technologies) are laser-printer sized and offer modest set-up and running...
- 3From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedTo the Editor: I recently read the News story in the March issue regarding Bruton's tyrosine kinase (BTK) immunokinase1, and it reminded me of work that I presented at Cold Spring Harbor way back in 2003 (ref. 2). On...
- 4From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedCloning by homologous recombination--recombineering--is a method for isolating large, specific fragments of DNA using enzymes, such as Red[alpha] and Red[beta] from lambda phage, that promote homologous recombination...
- 5From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedWilliam D. "Chip" Baird III has been appointed CFO of Amicus Therapeutics (Cranbury, NJ, USA). Baird brings over 15 years of experience in finance and strategic planning, most recently at PTC Therapeutics, where he...
- 6From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedIn March, the Supreme Court of the United States issued a unanimous decision--a rarity these days--in Mayo Collaborative Services, et al. [Mayo] v. Prometheus Laboratories, Inc. [Prometheus]. Writing for all nine...
- 7From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedThe ability to specifically upregulate genes in vivo holds great therapeutic promise. Here we show that inhibition or degradation of natural antisense transcripts (NATs) by single-stranded oligonucleotides or siRNAs can...
- 8From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedBen-Zion Weiner has been named as director of the board of directors of XTL Biopharmaceuticals (Herzliya, Israel). He brings to XTL his vast experience in pharmaceutical development gained from a 36-year career at Teva...
- 9From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedA new report concludes that industry funding does not skew trial outcomes, at least for rheumatoid arthritis drugs. Rheumatologist Nasim A. Khan and collaborators at the University of Arkansas for Medical Sciences in...
- 10From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedMethods for recovering genomic sequences of interest are among the most important tools in biotechnology, but many require laborious library generation and screening or several preparatory DNA amplification and assembly...
- 11From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedSome clinically important pathogens are recalcitrant to traditional vaccination strategies, including HIV, influenza and hepatitis C. Various factors can interfere with the production of broadly neutralizing antibodies...
- 12From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedThe newly opened UK Biobank (Stockport, UK) has appointed Sir Michael Rawlins as chairman. Rawlins, who has also served as chairman of the UK's National Institute of Health & Clinical Excellence (NICE) since its...
- 13From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedWe describe a computational method that infers tumor purity and malignant cell ploidy directly from analysis of somatic DNA alterations. The method, named ABSOLUTE, can detect subclonal heterogeneity and somatic...
- 14From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedThe world's largest data set on human genetic variation, the 1000 Genomes Project, is now available for free through Amazon Web Services. The arrangement with Amazon, spearheaded through the US National Institutes of...
- 15From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedTo the Editor: Transcription activator-like (TAL) effectors of Xanthomonas oryzae pv. oryzae (Xoo) contribute to pathogen virulence by transcriptionally activating specific rice disease-susceptibility (S) genes (1),...
- 16From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedThe private biotech sector represents commercial life science in its purest form: driven by both business and science, it is bright-eyed and innovative, unmolested by shareholder demands and relentlessly in pursuit of...
- 17From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedOn April 13, the Texas Medical Board by a vote of 10-4 approved guidelines for the use of investigational drugs, including stem cells, in the practice of medicine. The state is positioning itself as "the world's leader...
- 18From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedMonoclonal antibodies can be isolated using hybridomas, phage display or single-cell B-cell sorting followed by molecular cloning. But these methods are labor intensive and do not necessarily recover the antibodies that...
- 19From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedIn the version of this article initially published, in the Table 'Transgenic crop and/or traits receiving approval', Syngenta was credited with product MON 87460-4. Monsanto owns MON 87460-4. The error has been...
- 20From: Nature Biotechnology. (Vol. 30, Issue 5) Peer-ReviewedCompugen (Tel Aviv, Israel) has named Mary Haak-Frendscho as executive chairperson of its new S. San Francisco, California, office. Haak-Frendscho was most recently with Takeda Pharmaceutical. Additionally, John Hunter,...